Abstract:Background: Toxoplasmosis, caused by Toxoplasma gondii , poses serious health issues for humans and animals. Individuals with impaired immune systems are more susceptible to severe toxoplasmosis. Pregnant women infected by T. gondii can face the possibility of birth defects and miscarriages. While pyrimethamine and sulfadiazine are commonly used drugs in clinical practice, concerns over their side effects and resistance are on the rise. A spider peptide XYP1 isolated from Lycosa coelestis had potent anti-T. gondii effects, but it had a high synthesis cost and strong cytotoxicity. Methods: This study intended to modify XYP1 for producing derived peptides via amino acid truncation and substitution. The anti-T. gondii effect was evaluated by trypan blue staining assay and killing experiment of RH strain tachyzoites. The CCK8 and hemolysis assays were used to compare their safeties. The morphological changes of T. gondii were observed by scanning electron microscope and transmission electron microscope. In addition, the mechanism of XYP1 against T. gondii through RNA-sequencing was further explored. Results: In vivo and in vitro experiments revealed that XYP1-18 and XYP1-18-1 had excellent anti-T. gondii activity with lower cytotoxicity and hemolysis activity than XYP1. XYP1, XYP1-18, and XYP1-18-1 were able to disrupt the surface membrane integrity of T. gondii tachyzoites, forming pores and causing the disruption of organelles. Furthermore, RNA-sequencing analysis indicated that XYP1 could stimulate the host immune response to effectively eliminate T. gondii and lessen the host's inflammatory reaction. Conclusions: XYP1-18 had lower cytotoxicity and hemolysis activity than XYP1, as well as significantly extending the survival time of the mice. XYP1 played a role in host inflammation and immune responses, revealing its potential mechanism. Our research provided valuable insights into the development and application of peptide-based drugs, offering novel strategies and directions for treating toxoplasmosis.

Anti-Toxoplasma gondii effect of tylosin in vitro and in vivo

Synthesis, in Vitro and in Vivo Biological Evaluation of Dihydroartemisinin Derivatives with Potential Anti-Toxoplasma Gondii Agents.

Advances in the Study of Drugs with Action Against Toxoplasmosis

Evaluation of Potential Anti-Toxoplasmosis Efficiency of Combined Traditional Herbs in a Mouse Model

Anti-Toxoplasma gondii Effects of a Novel Spider Peptide XYP1 In Vitro and In Vivo

In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate against <i>Toxoplasma gondii</i>

Comprehensive Insights into the Development of Antitoxoplasmosis Drugs: Current Advances, Obstacles, and Future Perspectives

Anti-Toxoplasma Gondii Effect of Two Spider Venoms in Vitro and in Vivo

Anti-Toxoplasma gondii effects of XYP1-derived peptides and regulatory mechanisms of XYP1

Evaluation of Ursolic Acid Derivatives with Potential Anti-Toxoplasma Gondii Activity

Tylvalosin demonstrates anti-parasitic activity and protects mice from acute toxoplasmosis

Chemotherapeutics for Toxoplasma gondii : Molecular Biotargets, Binding Modes, and Structure–Activity Relationship Investigations

Treatment Methods of Traditional Chinese Medicine for Toxoplasmosis

Effect of the mitochondrial uncoupling agent BAM15 against the Toxoplasma gondii RH strain and Prugniaud strain

Anti-toxoplasmosis Effects of Oleuropein Isolated from Fraxinus Rhychophylla

Antiparasitic Effects of Oxymatrine and Matrine Against Toxoplasma Gondii in Vitro and in Vivo.

Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro

Evaluation of the Inhibition Effects of Natural Terpenoids on Toxoplasma gondii Tachyzoites

Synthesis and evaluation of in vitro and in vivo anti-Toxoplasma gondii activity of tetraoxane-substituted ursolic acid derivatives

<i>Anti-Toxoplasma gondii </i>Properties of Ginseng polysaccharides and saponins

Advance on Vaccine Against Toxoplasmosis